...
首页> 外文期刊>Vaccine >Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines
【24h】

Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines

机译:不同的巨细胞病毒候选疫苗免疫后,针对糖蛋白B抗原结构域2的体液免疫靶向I

获取原文
获取原文并翻译 | 示例

摘要

Glycoprotein B (gB) is a major component in several vaccines that are under development for prevention of disease by cytomegalovirus. It contains multiple determinants that are targets for neutralizing antibodies. One of them is site I of antigenic domain 2 (AD-2). The epitope, defined by short peptides, is quite conserved between different isolates. However, it is poorly immunogenic in natural infection. In this study we investigated the extent to which different vaccines, attenuated live Towne vaccine with or without priming with a canarypox virus coding for gB, or a recombinant gB vaccine adjuvanted with MF59, induced antibodies to this epitope. As in natural infection only a fraction of all subjects developed antibody responses against site I ofAD-2 following vaccination. We suggest that strategies that enhance immunogenicity of this epitope will improve vaccine efficacy.
机译:糖蛋白B(gB)是几种疫苗中的主要成分,这些疫苗正在开发中以预防巨细胞病毒引起的疾病。它包含多个中和抗体的决定簇。其中之一是抗原结构域2(AD-2)的I位。由短肽定义的表位在不同分离株之间非常保守。但是,它在自然感染中的免疫原性很差。在这项研究中,我们调查了不同的疫苗,带有或不带有编码gB的金丝雀痘病毒或带有MF59的重组gB疫苗引发的减毒活Towne疫苗诱导针对该表位的抗体的程度。如在自然感染中一样,在疫苗接种后,仅一小部分所有受试者产生针对AD-2位点I的抗体应答。我们建议增强该表位的免疫原性的策略将提高疫苗效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号